120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
妊娠期糖尿病与新生儿酰基代谢谱的关联：基于出生队列的实证研究
Authors Yang Y, Peng Y, Guo F, Jia C, Yu B
Received 22 August 2025
Accepted for publication 28 December 2025
Published 28 January 2026 Volume 2026:19 561443
DOI https://doi.org/10.2147/DMSO.S561443
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Pablo Corral
Yuqi Yang,1,* Yue Peng,2,* Fang Guo,1 Chenbo Jia,1 Bin Yu1
1Department of Medical Genetics, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People’s Republic of China; 2Department of Obstetrics, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Bin Yu, Email binyu@njmu.edu.cn
Aim: This study aimed to identify gestational diabetes mellitus (GDM)-associated neonatal acylcarnitines (ACs), assess maternal glycemic control’s impact on these ACs, and evaluate maternal lipids’ mediating role, supporting early metabolic risk stratification in offspring.
Methods: Tandem mass spectrometry (TMS) measured AC levels in 4,974 newborns (836 GDMs,4,138 controls). Generalized linear models assessed GDM-neonatal AC associations. Non-parametric tests assessed differences among no-GDM (2769), well-controlled GDM (129), and suboptimally controlled GDM groups (425). Mediation analysis identified factors affecting neonatal ACs. Maternal clinical data were extracted from the electronic medical record (EMR) system.
Results: Of the 31 acylcarnitine species, 19 were significantly associated with GDM. Relative to the control group, 18 ACs exhibited significantly elevated levels, specifically malonylcarnitine+3-hydroxybutyrylcarnitine (C3DC+C4OH), isovalerylcarnitine+methylbutyrylcarnitine (C5), glutarylcarnitine+3-hydroxyhexanoylcarnitine (C5DC+C6OH), hexanoylcarnitine (C6), methylglutarylcarnitine (C6DC), decanoylcarnitine (C10), decenoylcarnitine (C10:1), dodecanoylcarnitine (C12), dodecenoylcarnitine (C12:1), tetradecanoylcarnitine (C14), tetradecenoylcarnitine (C14:1), palmitoylcarnitine (C16), palmitoleylcarnitine (C16:1), 3-hydroxypalmitoleylcarnitine (C16:1OH), 3-hydroxypalmitoylcarnitine (C16OH), stearoylcarnitine (C18), 3-hydroxyoleoylcarnitine (C18:1-OH),and 3-hydroxystearoylcarnitine (C18OH); only linoleoylcarnitine (C18:2) showed a significant decrease. In groups with progressively impaired glycemic control, triglyceride (TG) levels (P < 0.001) and propionylcarnitine (C3) levels (P = 0.02) exhibited a significant increasing trend, whereas high-density lipoprotein cholesterol (HDL-C) (P = 0.01) and C18:2 levels (P = 0.02) showed a consistent decreasing trend. Mediation analysis further demonstrated that maternal TG levels exerted a significant positive mediating effect on the elevation of neonatal C3 levels (10.7%, 95% CI: 0.0016, 0.0182, P = 0.006), whereas a significant masking effect was observed on C10:1 levels (− 14.27%, 95% CI: − 0.0006, − 0.0001, P < 0.001). Additionally, maternal HDL-C levels exhibited significant masking effects on most acylcarnitine indicators, with the only exception being a significant positive mediating effect on C18:2 levels (2.94%,95% CI: − 0.0018, − 0.0001, P = 0.0186).
Conclusion: GDM correlates with offspring AC levels, with TG and HDL-C partially mediating this relationship. Newborn fat oxidation metabolism is influenced by maternal factors from birth.
Keywords: gestational diabetes mellitus, fatty acid metabolism, acylcarnitine, β-oxidation
1Department of Medical Genetics, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People’s Republic of China; 2Department of Obstetrics, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Bin Yu, Email binyu@njmu.edu.cn
Aim: This study aimed to identify gestational diabetes mellitus (GDM)-associated neonatal acylcarnitines (ACs), assess maternal glycemic control’s impact on these ACs, and evaluate maternal lipids’ mediating role, supporting early metabolic risk stratification in offspring.
Methods: Tandem mass spectrometry (TMS) measured AC levels in 4,974 newborns (836 GDMs,4,138 controls). Generalized linear models assessed GDM-neonatal AC associations. Non-parametric tests assessed differences among no-GDM (2769), well-controlled GDM (129), and suboptimally controlled GDM groups (425). Mediation analysis identified factors affecting neonatal ACs. Maternal clinical data were extracted from the electronic medical record (EMR) system.
Results: Of the 31 acylcarnitine species, 19 were significantly associated with GDM. Relative to the control group, 18 ACs exhibited significantly elevated levels, specifically malonylcarnitine+3-hydroxybutyrylcarnitine (C3DC+C4OH), isovalerylcarnitine+methylbutyrylcarnitine (C5), glutarylcarnitine+3-hydroxyhexanoylcarnitine (C5DC+C6OH), hexanoylcarnitine (C6), methylglutarylcarnitine (C6DC), decanoylcarnitine (C10), decenoylcarnitine (C10:1), dodecanoylcarnitine (C12), dodecenoylcarnitine (C12:1), tetradecanoylcarnitine (C14), tetradecenoylcarnitine (C14:1), palmitoylcarnitine (C16), palmitoleylcarnitine (C16:1), 3-hydroxypalmitoleylcarnitine (C16:1OH), 3-hydroxypalmitoylcarnitine (C16OH), stearoylcarnitine (C18), 3-hydroxyoleoylcarnitine (C18:1-OH),and 3-hydroxystearoylcarnitine (C18OH); only linoleoylcarnitine (C18:2) showed a significant decrease. In groups with progressively impaired glycemic control, triglyceride (TG) levels (P < 0.001) and propionylcarnitine (C3) levels (P = 0.02) exhibited a significant increasing trend, whereas high-density lipoprotein cholesterol (HDL-C) (P = 0.01) and C18:2 levels (P = 0.02) showed a consistent decreasing trend. Mediation analysis further demonstrated that maternal TG levels exerted a significant positive mediating effect on the elevation of neonatal C3 levels (10.7%, 95% CI: 0.0016, 0.0182, P = 0.006), whereas a significant masking effect was observed on C10:1 levels (− 14.27%, 95% CI: − 0.0006, − 0.0001, P < 0.001). Additionally, maternal HDL-C levels exhibited significant masking effects on most acylcarnitine indicators, with the only exception being a significant positive mediating effect on C18:2 levels (2.94%,95% CI: − 0.0018, − 0.0001, P = 0.0186).
Conclusion: GDM correlates with offspring AC levels, with TG and HDL-C partially mediating this relationship. Newborn fat oxidation metabolism is influenced by maternal factors from birth.
Keywords: gestational diabetes mellitus, fatty acid metabolism, acylcarnitine, β-oxidation